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Abstract
Objectives:  To  review  the  current  evidence  base  for  the  diagnosis  and  management  of  the
childhood  epilepsies  and  to  draw  attention  to  the  current  gaps  in  this  evidence  base.  The  focus
will be  on  therapeutic  aspects.  Current  International  League  Against  Epilepsy  (ILAE)  terminol-
ogy will  be  described  and  used  throughout  the  discussion.  The  review  will  draw  attention  to
recent advances  that  have  been  made  in  both  our  understanding  and  treatment  of  the  childhood
epilepsies.  Potential  future  directions  for  research  and  treatment  options  will  be  discussed.
Sources: Original  articles  relevant  to  the  subject  were  obtained  from  the  MedLine  database
using pertinent  MeSH  terms.  Relevant  papers  were  read  and  assimilated.  Citation  searching  was
used.
Summary of  the  ﬁndings:  Epilepsy  is  a  major  cause  of  global  disease  burden.  Childhood  epilep-
sies are  a  heterogeneous  group  of  conditions.  A  multi-axial  diagnostic  approach  should  be
taken prior  to  making  treatment  and  management  decisions  for  any  individual  patient.  For
the majority  of  patients,  successful  control  of  seizures  can  be  achieved  with  a  single  medica-
tion. However,  a  signiﬁcant  minority  develops  refractory  disease.  Epilepsy  surgery  can  provide
cure for  a  carefully  selected  group  of  these  cases.
Conclusions:  There  remain  signiﬁcant  gaps  the  evidence  base  for  treatment  in  several  areas  of
childhood  epilepsy.  Concerted  multi-center  efforts  should  be  made  to  try  to  close  these  gaps.
A personalized  medicine  approach  may  help  to  reduce  the  proportion  of  refractory  cases  of
childhood epilepsy  in  future.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved. Please cite this article as: Zuberi SM, Symonds JD. Update on diagnosis and management of childhood epilepsies. J Pediatr (Rio J).
2015;91:S67--77.
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Atualizac¸ão  sobre  o  diagnóstico  e  tratamento  de  epilepsias  da  infância
Resumo
Objetivos:  Analisar  a  base  de  evidências  atual  para  o  diagnóstico  e  tratamento  das  epilep-
sias da  infância  e  chamar  a  atenc¸ão  para  as  lacunas  atuais  nessa  base  de  evidências.
O foco  será  os  aspectos  terapêuticos.  A  terminologia  atual  da  Liga  Internacional  contra
a Epilepsia  (ILAE)  será  descrita  e  utilizada  na  discussão.  A  análise  chamará  a  atenc¸ão
para os  recentes  avanc¸os  em  nosso  entendimento  e  no  tratamento  das  epilepsias  da
infância.  Serão  discutidas  possíveis  orientac¸ões  futuras  para  as  opc¸ões  de  pesquisa  e
tratamento.
Fontes de  dados:  Trabalhos  originais  relevantes  para  o  assunto  foram  obtidos  da  base  de  dados
MedLine usando  termos  relevantes  do  MeSH.  Os  trabalhos  relevantes  foram  lidos  e  assimilados.
Foi usada  pesquisa  de  citac¸ões.
Resumo  dos  dados: A  epilepsia  é  uma  das  maiores  causas  da  carga  global  de  doenc¸as.  As  epilep-
sias da  infância  representam  um  grupo  heterogêneo  de  doenc¸as.  Uma  abordagem  multiaxial
do diagnóstico  deve  ser  realizada  antes  da  tomada  de  decisões  de  tratamento  de  qualquer
paciente  individual.  Na  maioria  dos  pacientes,  o  controle  bem-sucedido  das  crises  pode  ser
obtido com  uma  única  medicac¸ão.  Contudo,  uma  minoria  signiﬁcativa  desenvolve  doenc¸a
refratária. A  cirurgia  de  epilepsia  pode  curar  um  grupo  cuidadosamente  selecionado  desses
casos.
Conclusões:  Ainda  existem  lacunas  signiﬁcativas  na  base  de  evidências  de  tratamento  em  diver-
sas áreas  de  epilepsia  da  infância.  Devem  ser  envidados  esforc¸os  multicêntricos  concertados
para tentar  fechar  essas  lacunas.  Uma  abordagem  médica  personalizada  pode  ajudar  a  reduzir
a proporc¸ão  de  casos  refratários  de  epilepsia  da  infância  no  futuro.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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Table  1  International  League  Against  Epilepsy  operational
deﬁnition  of  epilepsy  2014.6
A  disease  of  the  brain  deﬁned  by  any  of  the  following
conditions
1. At  least  two  unprovoked  (or  reﬂex)  seizures  occurring
>24 h  apart
2.  One  unprovoked  (or  reﬂex)  seizure  and  a  probability  of
further  seizures  similar  to  the  general  recurrence  risk  (at
least 60%)  after  two  unprovoked  seizures,  occurring  over
the next  10  years
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pidemiology
pilepsy  is  the  most  prevalent  chronic  neurological  dis-
ase  in  the  world,  with  an  estimated  65  million  people
ffected.1 Severe  epilepsy  ranks  as  the  fourth  largest
ause  of  global  disease  burden.2 Crude  incidence  estimates
or  epilepsy  vary  from  15  to  113  per  100,000  per  year,
epending  on  the  population  studied.3 The  incidence  of
pilepsy  in  childhood  is  more  than  twice  that  in  the  adult
opulation.4
eﬁnitions
pilepsy  has  been  conceptually  deﬁned  as  a  disorder  of
he  brain  characterized  by  an  enduring  predisposition  to
enerate  epileptic  seizures.  An  epileptic  seizure  is  a  tran-
ient  occurrence  of  signs  and/or  symptoms  due  to  abnormal
xcessive  or  synchronous  neuronal  activity  in  the  brain.5
o  facilitate  the  practical  application  of  epilepsy  as  a
iagnostic  term,  the  International  League  Against  Epilepsy
ILAE)  ﬁnalized  an  operational  deﬁnition  of  epilepsy  in  2014
Table  1).6 It  is  perhaps  most  helpful  to  conceptualize
pilepsy  not  as  a  single  condition,  but  as  a  group  of  condi-
ions,  ‘‘the  epilepsies’’,  reﬂecting  the  recognition  that  the
nderlying  causes  of  epileptic  seizures  are  both  varied  and
umerous,  and  that  the  clinical  manifestations  of  abnormal
3
4
53.  Diagnosis  of  an  epilepsy  syndrome
xcessive  or  synchronous  neuronal  activity  are  heteroge-
eous.
iagnosis
hen  considering  a diagnosis  of  epilepsy,  a  multi-axial
pproach  is  recommended.7 The  following  axes  should  be
onsidered:
.  Is  the  diagnosis  epilepsy?
.  What  are  the  seizure  types?. Can  the  diagnosis  of  an  established  epilepsy  syndrome  be
made?
.  What  is  the  underlying  cause  for  the  epilepsy?
.  Are  there  any  comorbidities?
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iDiagnosis  and  management  of  childhood  epilepsies  
Establishing  whether  the  diagnosis  is  epilepsy  or
not
Accuracy  of  diagnosis  is  paramount,  since  a  diagnosis  of
epilepsy  can  have  signiﬁcant  implications  for  patients,  their
families,  and  therapeutic  management.  However,  making
a  diagnosis  of  epilepsy  can  be  challenging,  since  there
are  a  number  of  paroxysmal  conditions  for  which  the  clin-
ical  history  may  resemble  that  of  an  epileptic  seizure,
and  because  there  is  no  deﬁnitive  diagnostic  investiga-
tion  for  this  condition.  Misdiagnosis  rates  in  epilepsy  have
traditionally  been  high.  Of  233  children  referred  to  a  ter-
tiary  epilepsy  center  in  Denmark,  87  (39%)  were  found  by
expert  assessment  not  to  have  epilepsy,  and  of  these  35
(40%)  had  been  started  on  anti-epileptic  drugs  (AEDs).8 The
most  frequently  observed  differential  diagnoses  were  non-
epileptic  staring  spells  (52.8%),  psychogenic  non-epileptic
seizures  (10.3%),  syncope  (3.4%),  dystonia  (3.4%),  and  para-
somnias  (3.4%).  Misdiagnosis  of  non-epileptic  events  when
the  true  diagnosis  is  epilepsy  appears  to  be  less  common.
In  a  Dutch  study  that  included  888  children  referred  to  a
tertiary  center  with  paroxysmal  events,  19/124  (5.6%)  chil-
dren  who  had  been  referred  with  multiple  unclear  events
were  given  a  diagnosis  of  epilepsy.9 Initial  assessment  by
a  practitioner  with  expertise  and  experience  in  epilepsy
diagnosis  is  thought  to  signiﬁcantly  reduce  misdiagnosis
rates.
In  many  cases,  the  diagnosis  of  an  epileptic  or  non-
epileptic  event  can  be  based  on  an  accurate  description  of
the  episode  or  episodes  by  the  patient  and  witnesses,  with
no  further  investigations  necessary.  The  widespread  use  of
smartphones  has  greatly  facilitated  the  diagnosis  of  parox-
ysmal  events.  When  events  are  recurrent  and  there  is  doubt
about  their  nature,  parents  should  be  strongly  encouraged
to  capture  them  on  video.  The  ILAE  has  built  up  an  excellent
online  resource10 where  clinicians  can  view  video  examples
of  epileptic  and  non-epileptic  events.
Syncopal  events  can  often  be  differentiated  from  epilep-
tic  seizures  by  the  patient’s  description  of  how  they  felt
before  the  collapse.  Typical  prodromal  symptoms  of  syncope
are  dizziness,  visual  loss,  nausea,  sweating,  and  tinnitus.  In
all  cases  or  collapse,  it  is  advisable  of  obtain  a  12-lead  elec-
trocardiogram,  with  particular  attention  to  measurement  of
the  corrected  QT  interval,  since  cardiac  arrhythmia  is  an
important  differential.11
Description  of  seizure  types
Once  a  clear  description  of  the  event(s)  has  been  obtained,
if  they  are  thought  to  be  epileptic,  the  clinician  should  try
to  classify  the  seizure  type(s).  Table  2  details  the  current
ILAE  classiﬁcation  of  seizure  types.  Generalized  seizures  are
conceptualized  as  beginning  within,  and  rapidly  engaging
bilateral  networks  within  the  brain,  whereas  focal  seizures
originate  within  networks  limited  to  one  hemisphere.  Focal
seizures  may  progress  to  engage  both  hemispheres,  resulting
in  bilateral  convulsive  features.  An  electroencephalogram
(EEG)  is  a  useful  adjunct  to  seizure  type  classiﬁcation,  par-
ticularly  in  focal  epilepsies  for  which  focal  epileptiform
activity  may  help  identify  a  lobar  location.
‘
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yndrome  classiﬁcation
y  analyzing  the  clinical  details  of  a patient’s  epilepsy,
ncluding  seizure  types,  age  of  onset,  and  associated  comor-
idities,  it  may  be  possible  to  diagnose  a  speciﬁc  epilepsy
yndrome.  Many  epilepsy  syndromes  are  associated  with  par-
icular  ﬁndings  on  EEG,  therefore  this  investigation  can  be
ery  helpful  in  assisting  syndrome  classiﬁcation.  Achieving
 syndromic  diagnosis  is  important,  since  it may  inform
herapeutic  decisions,  further  investigations,  and  prognosis.
he  ILAE  website  provides  clinical  and  EEG  features  of  31
pilepsy  syndromes.10 Estimates  for  the  proportion  of  child-
ood  epilepsy  cases  that  can  be  diagnosed  with  an  epilepsy
yndrome  have  ranged  between  15.7%  and  37.1%,  depending
n  the  population  included.12--14 The  most  prevalent  epilepsy
yndromes  of  childhood  appear  to  be  benign  epilepsy  of
hildhood  with  centro-temporal  spikes  (BCECTS),  childhood
bsence  epilepsy  (CAE),  juvenile  absence  epilepsy  (JAE),
uvenile  myoclonic  epilepsy  (JME),  and  West  syndrome  (WS).
any  of  the  epilepsies  that  do  not  conform  to  a  syndromic
iagnosis  can  still  be  described  in  terms  of  seizure  types  and
tiology  (Table  3).
tiology
n  most  epilepsies,  investigation  for  an  underlying  eti-
logy  is  warranted,  regardless  as  to  whether  or  not  an
pilepsy  syndrome  diagnosis  has  been  made.  The  excep-
ions  to  this  rule  are  typical  cases  of  BCECTS,  CAE,  JAE,
nd  JME.  Although  these  epilepsies  all  have  a  principally
enetic  etiology,  genetic  investigation  is  not  currently  clini-
ally  useful  since  multiple  susceptibility  genes  are  involved
nd  there  is  no  established  correlation  between  genetic
ndings  and  either  prognosis  or  therapeutic  management.
hese  same  syndromes  are  very  rarely  associated  with
tructural  brain  abnormalities,  so  neuroimaging  is  also  not
ecessary.15 In  all  other  cases  of  childhood-onset  epilepsy,
ncluding  atypical  cases  of  the  above-listed  syndromes,
euroimaging  is  indicated.  The  purpose  of  neuroimaging
s  to  identify  any  causative  structural  brain  lesion.  Some
esions,  such  as  neoplasms,  may  require  immediate  mana-
ement,  whilst  others,  such  as  focal  cortical  dysplasia,
ay  prove  to  be  surgically  remediable  targets  further
own  the  line.  Abnormal  neuroimaging  is  found  in  50%
f  new  childhood-onset  epilepsy  in  which  there  are  focal
eizures,  and  in  15--20%  of  cases  imaging  studies  provide
seful  information  on  etiology  and/or  seizure  focus.16 Mag-
etic  resonance  imaging  (MRI)  is  the  imaging  modality  of
hoice.
The  ﬁrst  signiﬁcant  attempt  at  reclassifying  the  epilep-
ies  in  line  with  modern  understanding  of  the  disease  and
ts  mechanisms  was  made  by  the  ILAE  in  2010.  The  principal
hanges  to  ofﬁcial  ILAE  nomenclature  focused  on  etiological
ategorization.  The  terms  ‘‘idiopathic,’’  ‘‘symptomatic,’’
nd  ‘‘cryptogenic’’  were  replaced  by  the  more  precise
erms  ‘‘genetic,’’  ‘‘structural,’’  and  ‘‘metabolic.’’  The
nclusion  of  further  etiological  categories  ‘‘immune’’  and
‘infectious’’  is  currently  under  discussion  (Table  4).
Overall,  it  is  estimated  that  approximately  40--60%  of
hildhood  epilepsies  have  genetic  etiology,  and  25%  have
tructural  or  metabolic  etiology,  whilst  approximately  25%  of
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Table  2  International  League  Against  Epilepsy  classiﬁcation  of  seizure  types.
Generalized  seizures
Generalized  tonic--clonic  Bilaterally  increased  tone,  followed  by  sustained  bilateral  rhythmic  limb  jerking.
Clonic Sustained  bilateral  rhythmic  jerking.
Absence
Typical  absence  Abrupt  onset  of  altered  awareness.  Memory  of  events  usually  impaired.  Oral  and
manual automatisms  are  common.  Clonic  movements  of  parts  of  the  face  may  occur.
Atypical absence Less  abrupt  onset  and  offset  than  typical  absence.  May  be  associated  with  loss  of
muscle tone,  or  subtle  myoclonic  jerks.  Often  longer  than  typical  absences.  Alteration
in awareness  variable.
Myoclonic  absence  Rhythmic  myoclonic  jerks  of  the  shoulders  and  arms  with  tonic  abduction,  resulting  in
progressive  lifting  of  the  arms  during  the  seizure.  The  myoclonic  jerks  are  typically
bilateral,  but  may  be  unilateral  or  asymmetric.  Last  10--60  s.  Alteration  in  awareness
variable.
Absence with  eyelid  myoclonia  Absence  seizures  accompanied  by  brief,  repetitive,  often  rhythmic,  fast  myoclonic  jerks
of the  eyelids,  with  simultaneous  upward  deviation  of  the  eyeballs  and  extension  of  the
head. Seizures  are  typically  very  brief  (<6  s  in  duration)  and  multiple  seizures  occur  on  a
daily basis.  Mostly  awareness  is  retained.
Tonic Bilaterally  increased  tone  of  the  limbs  lasting  seconds  to  a  minute.  Often  occur  out  of
sleep and  in  runs  of  varying  intensity.  The  individual  is  unaware  during  these  events.
Individuals  may  make  an  expiratory  sound  at  onset.  May  cause  drop  attacks.
Atonic Sudden  loss  or  diminution  of  muscle  tone  without  apparent  preceding  myoclonic  or
tonic features.  Very  brief  (<2  s)  and  may  involve  the  head,  trunk,  or  limbs.
Myoclonic
Myoclonic Single  or  series  of  jerks  (brief  muscle  contractions).  Each  jerk  is  typically  milliseconds
in duration.
Negative  myoclonus  Brief  cessation  of  background  muscle  tone,  lasting  less  than  500  ms.  The  resulting
movement  produced  can  have  two  components,  an  initial  loss  of  posture  caused  by  the
negative myoclonus,  and  a  subsequent  voluntary,  compensatory  movement  to  restore
posture.  May  occur  in  isolation  or  in  a  series.
Myoclonic--atonic  Myoclonic  seizure  followed  by  an  atonic  seizure.  Sometimes  a  series  of  myoclonic  jerks
occurs prior  to  the  atonia.  The  head  and  limbs  are  affected,  typically  resulting  in  rapid
fall.
Myoclonic--tonic  Myoclonic  seizure  followed  by  a  tonic  seizure.  Sometimes  a  cluster  of  myoclonic  jerks
occurs prior  to  the  increased  tone.
Focal seizures:  can  be  classiﬁed  by  features,  and/or  laterality,  and/or  lobar  localization
By features  (clinical):  one  or  more  type  of  feature  may  be  present  during  any  single  focal  seizure
Aura Auras  are  subjective  and  may  be  sensory  or  experiential.  A  sensory  aura  involves  a
sensation without  an  objective  clinical  sign,  which  may  be  visual,  auditory,  olfactory,
epigastric,  etc.  An  experiential  aura  involves  affective,  mnemonic,  or  perceptual
subjective  phenomena,  including  depersonalization  and  hallucinatory  events.
Motor A  motor  feature  involves  motor  activity  and  may  consist  of  an  increase  (positive)  or
decrease  (negative)  in  muscle  contraction.
Autonomic  Characterized  by  autonomic  phenomena,  which  can  involve  cardiovascular,
gastrointestinal,  vasomotor,  and  thermoregulatory  functions.  Examples  include
palpitations,  nausea,  butterﬂies,  hunger,  chest  pain,  urge  to  urinate  or  defecate,
goosebumps,  sexual  sensation,  feeling  hot  or  cold,  piloerection,  pallor,  tachycardia  or
bradycardia/asystole,  ﬂushing,  pupillary  changes,  and  lacrimation.
Dyscognitive  Involves  altered  awareness  or  responsiveness.
By hemispheric  localization  (clinical  or  electrophysiological)
Right Indications  of  hemispheric  localization  may  be  subtle,  particularly  in  seizures  that
rapidly engage  bilateral  networks.  Head  turning,  eye  deviation,  and  unilateral  clonic
movements  all  lateralize  to  the  contralateral  hemisphere.Left
By lobar  localization  (clinical  or  electrophysiological)
Frontal  Frontal  lobe  seizures  are  usually  brief.  Motor  features  are  prominent.  There  may  be
vocalization,  bizarre  behavior,  head  and  eye  deviation,  and  urinary  incontinence.
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Table  2  (Continued)
Temporal Characterized  by  behavioral  arrest  and  dyscognitive  features.  Automatisms  and  auras
are common.
Parietal  Ictal  features  are  often  subjective,  and  include  positive  and/or  negative  sensory
features such  as  paresthesia,  disorientation,  and  complex  visual  hallucinations.
Occipital Characterized  by  visual  aura,  typically  multi-colored  shapes.
Epileptic  Spasms
Sudden  ﬂexion,  extension  or  mixed  ﬂexion-extension  of  proximal  and  truncal  muscles,  lasting  1--2  s,  i.e.,  longer  than  a
myoclonic jerk  (which  lasts  milliseconds)  but  not  as  long  as  a  tonic  seizure  (which  lasts  >2  s).  Spasms  typically  occur  in  a
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Cseries, usually  on  wakening.  Subtle  forms  may  occur  with  only
bilaterally symmetric,  asymmetric,  or  unilateral.
cases  remain  of  unknown  cause.17 Increases  in  the  sensitivity
and  availability  of  genetic,  biochemical,  and  neuroimaging
testing  will  result  in  a  fall  in  the  proportion  of  unknown  eti-
ology  cases  in  future.14 The  genetic  causes  of  both  metabolic
and  structural  epilepsies  are  being  increasingly  understood,
so  the  boundaries  between  these  categories  are  becoming
progressively  blurred.  In  the  future,  the  term  ‘‘genetic’’
may  well  become  outdated,  to  be  replaced  by  more  precise
terminology.
For  children  in  whom  epilepsy  presents  at  a  young  age,
or  is  associated  with  developmental  regression  or  develop-
mental  impairment,  if  no  deﬁnitive  etiological  diagnosis  has
been  made  through  neuroimaging,  it  is  reasonable  to  con-
sider  investigation  for  an  underlying  genetic  or  metabolic
cause.  The  approach  to  such  investigation  will  depend  on
T
e
i
h
Table  3  Most  frequently  encountered  childhood  epilepsy  syndrom
Epilepsy  syndrome  Proportion  of  total
childhood  epilepsy
Age  of  pr
West  syndrome15 2--3%  3--12  mon
Childhood absence  epilepsy15 2--5%  8--12  year
Benign childhood  epilepsy  with
centro-temporal  spikes15
3--8%  3--14  year
Juvenile absence  epilepsy15 1--4%  8--20  year
Juvenile myoclonic  epilepsy15 5--11%  8--25  year movement,  grimacing,  or  head  nodding.  Spasms  may  be
he  following:  the  nature  of  the  patient’s  epilepsy  and
ssociated  comorbidities;  the  population  background  of  the
atient  and  the  prevalence  of  speciﬁc  genetic/metabolic
onditions  within  that  population;  and  the  availability  of
peciﬁc  diagnostic  testing  locally  or  regionally.  Identifying
 metabolic  etiology  may  have  signiﬁcant  implications  for
reatment  approach.
omorbiditieshe  most  commonly  observed  comorbidities  in  childhood
pilepsy  are  developmental  impairments,  learning  disabil-
ties,  autism  spectrum  disorders  (ASD),  attention  deﬁcit
yperactivity  disorder  (ADHD),  and  behavioral  problems.
es.
esentation  Description  of  syndrome
ths  Infantile  spasms  with  associated
hypsarrhythmia  on  EEG.  Often  secondary  to
structural  brain  lesions.  Global  developmental
impairment  is  typically  seen.
s  Multiple  absence  seizures  per  day  in  an
otherwise  healthy  child.  Absences  can
invariably  be  provoked  by  hyperventilation  and
are associated  with  2.5--3.5  Hz  generalized
spike-wave  discharges  on  EEG
s  Brief  hemifacial  seizures  that  may  secondarily
generalize  if  they  occur  nocturnally.  EEG  is
characteristic,  showing  a  normal  background
with high  amplitude  sharp  waves  in  the
centro-temporal  regions,  which  are  activated
by drowsiness  and  sleep.  98%  of  children  are
seizure-free  off  medication  by  aged  18.
s  Relatively  infrequent  typical  absence  seizures
as well  as  generalized  convulsive  seizures  in  an
otherwise  normal  child  or  young  adult.
Generalized  epileptiform  discharges  are  seen
on interictal  EEG.
s  Frequent  myoclonic  seizures  that  are  more
prominent  in  the  morning  in  an  otherwise
normal  child  or  young  adult.  Most  patients  also
have  generalized  convulsive  seizures.
Generalized  epileptiform  discharges  are  seen
on interictal  EEG.
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Table  4  International  League  Against  Epilepsy  (ILAE)  etiological  classiﬁcation  of  epilepsy.
Old  ILAE  etiological  classiﬁcation7 Proposed  new  ILAE  etiological  classiﬁcation10
Idiopathic  A  syndrome  that  is  only  epilepsy,  with  no
underlying  structural  brain  lesion  or  other
neurologic  signs  or  symptoms.  Typically
age-dependent  epilepsy  syndromes.
Genetic  Epilepsies  in  which  a  genetic  etiology  has  been
proven,  or  can  be  deduced.  Most  epilepsies
previously  considered  idiopathic  are  now
considered  genetic.
Symptomatic  Epilepsy  in  which  the  seizures  are  a  result
of and  identiﬁable  disease  process,  such  as
an inborn  error  or  metabolism,  CNS
infection,  or  structural  brain  lesion.
Structural  Epilepsies  secondary  to  an  identiﬁable  structural
brain  lesion.  The  lesion(s)  may  be  congenital  (e.g.
lissencephaly),  or  acquired  (e.g.  traumatic),
static  or  progressive  (e.g.  neoplasm).  Some
structural  epilepsies  are  genetically  determined
(e.g.  tuberous  sclerosis)
Cryptogenic  Epilepsy  in  which  the  seizures  are  believed
to be  symptomatic,  but  no  identiﬁable
etiology  has  been  identiﬁed.
Metabolic  Epilepsies  secondary  to  inherited  metabolic
disease  where  the  epilepsy  is  considered  as  a
result  of  the  metabolic  derangement.
Immune  Epilepsies  secondary  to  a  pathological
immune-mediated  process,  where  there  is
evidence  of  CNS  inﬂammation  (e.g.  autoimmune
encephalitis).
Infectious  Epilepsies  secondary  to  infection  such  as  cerebral
malaria,  or  viral  encephalitis.
Unknown  Epilepsies  in  which  no  identiﬁable  cause  has  been
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Aiven  that  epilepsy  is  a  disorder  affecting  the  brain,  it  does
ot  come  as  a  surprise  that  these  comorbidities  have  a
eurological  basis.  Recently,  genetic  studies  have  demon-
trated  a  signiﬁcant  amount  of  genetic  overlap  between
pilepsy  and  other  neurodevelopmental  disorders,  suggest-
ng  that  they  all  have  related  neurobiological  determinants.
verall,  it  has  been  estimated  that  80%  of  children  with
pilepsy  have  cognitive,  psychosocial,  or  executive  function
roblems.18 30%  of  children  with  epilepsy  have  developmen-
al  delay,  25%  have  language  delay,  5--15%  have  ASD,  and
0--30%  have  ADHD.19--22 Recognition  and  management  of
hese  co-morbidities  is  essential,  since  they  can  often  be
igger  priorities  for  the  family  than  the  epileptic  seizures
hemselves.
he  role  of  the  EEG
s  highlighted  above,  the  EEG  is  a  useful  tool  to  assist  the
linician  in  the  classiﬁcation  of  seizure  types  and  epilepsy
yndromes.  However  it  must  be  emphasized  that  EEG  should
ot  be  used  as  a  diagnostic  test  for  epilepsy,  since  it  has
oth  poor  speciﬁcity  and  sensitivity.  One-third  of  patients
ith  epilepsy  will  have  a  completely  normal  interictal  EEG,9
hilst  5%  of  children  without  epilepsy  will  demonstrate  frank
pileptiform  abnormalities.23 When  there  is  clinical  doubt
s  to  whether  episodes  that  are  occurring  frequently  are
pileptic  or  not,  video-telemetry  or  ambulatory  EEG  can  be
ery  useful,  since  most  epileptic  events  will  have  an  EEG
orrelate.
anagementanagement  of  childhood  epilepsy  must  be  holistic,  giving
ue  consideration  to  the  individual  needs  and  expectations
f  the  patient  and  their  family.  The  concepts  of  ‘‘epilepsy’’
e
o
ﬁfound,  nor  can  be  deduced.
nd  ‘‘the  epilepsies’’  are  not  easy  to  grasp,  and  a  key
ole  of  the  clinician  is  to  help  the  patient  and  their
amily  make  sense  of  a  condition  that  has  traditionally
een  misunderstood  and  stigmatized.  Expert  management
elies  on  having  a  sound  knowledge  of  the  pharmacological
reatment  options,  including  their  indications,  interactions,
nd  side-effect  proﬁles.  Non-pharmacological  treatment
ptions  include  epilepsy  surgery,  the  ketogenic  diet,  and
eurostimulation  techniques.  Non-pharmacological  treat-
ent  may  allow  some  children  whose  epilepsy  is  refractory
o  medical  treatment  to  become  seizure-free,  and  may
ubstantially  reduce  the  seizure  burden  for  others.  Manag-
ng  epilepsy  is  about  more  than  controlling  seizures,  and
anagement  within  a multidisciplinary  team  may  be  the
ptimum  way  to  ensure  that  all  of  a  child’s  epilepsy-related
eeds  are  met.24 Such  a team  may  include  pediatricians
r  pediatric  neurologists,  neurophysiologists,  psychologists,
ccupational  therapists,  physiotherapists,  speech  and  lan-
uage  therapists,  specialist  nurses,  dieticians,  radiologists,
nd  surgeons.
ndications  for  starting  therapy
n  the  Dutch  study  of  epilepsy  in  childhood,  after  a  sin-
le  unprovoked  epileptic  seizure,  46%  of  children  were
ound  to  have  no  further  seizures  over  a  2-year  follow-up
eriod.25 Based  on  this  high  non-recurrence  rate,  coupled
ith  good  evidence  that  early  AED  treatment  does  not  inﬂu-
nce  long-term  seizure  outcome,26 it  is  generally  advised
hat  treatment  is  not  started  following  a  single  seizure.27
fter  two  unprovoked  seizures,  the  probability  of  a  third
vent  ranges  from  60%  to  90%,28 and  therefore  consideration
f  treatment  initiation  is  reasonable.
Nonetheless,  treatment  initiation  cannot  be  simpli-
ed  to  ‘‘one  seizure  =  no  treatment;  more  than  one
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seizure  =  treatment.’’  The  recently  adopted  ILAE  opera-
tional  deﬁnition  of  epilepsy  (Table  1)  recognizes  that,  in
some  circumstances,  such  as  the  presence  of  structural
or  metabolic  etiology,  the  risk  of  recurrence  after  a  sin-
gle  seizure  is  as  high  as  it  is  after  two  seizures  in  the
general  population.6 Conversely,  certain  childhood  epilepsy
syndromes,  particularly  BCECTS  and  Panayiotopoulos  syn-
drome,  typically  follow  a  course  in  which  very  few  seizures
are  followed  by  complete  remission,  and  it  is  reasonable
to  avoid  treating  many  children  with  these  syndromes  with
medication.29,30 The  decision  on  whether  to  start  treatment
is  therefore  multifaceted  and  must  bear  in  mind  the  fol-
lowing:  age,  syndromic  diagnosis  if  applicable,  etiology,  and
acceptability  of  a  further  seizure  (which  may  be  reduced  if
previous  seizures  have  been  prolonged  or  traumatic).
Goals  of  therapy
The  ideal  goal  of  AED  therapy  is  cessation  of  epileptic
seizures  without  undesirable  side  effects.  Treating  seizures
is  desirable,  as  they  are  frightening  for  families;  can  directly
lead  to  medical  complications,  such  as  injury  or  aspiration;
and  may  interfere  with  education,  leisure,  or  employment.
The  term  epileptic  encephalopathy  is  used  to  describe
epilepsies  in  which  epileptic  activity  itself  is  believed  to
contribute  to  severe  cognitive  and  behavioral  impairments
above  and  beyond  what  would  be  expected  from  the  under-
lying  pathology  alone.31 Examples  of  epilepsies  in  which
effective  control  of  epileptic  activity  appears  to  go  hand
in  hand  with  improved  cognitive  performance  are  WS  and
Landau--Kleffner  syndrome,  otherwise  known  as  acquired
epileptic  aphasia.  The  relative  contribution  of  the  underly-
ing  etiology  versus  ongoing  epileptic  activity  --  both  clinical
seizures  and  subclinical  epileptiform  activity  seen  on  EEG
-- to  cognitive  and  behavioral  impairment  in  people  with
epilepsy  will  vary  in  different  epilepsy  syndromes.  Even  in
so-called  ‘‘benign’’  epilepsy  syndromes,  many  children  will
have  speciﬁc  or  general  cognitive  impairment.  The  term
benign  is  therefore  likely  to  disappear  from  the  epilepsy
lexicon  in  time.  Parents  must  be  aware  that  controlling  the
seizures  may  not  have  any  impact  on  associated  learning
disability.
Effectiveness  of  therapy
Overall,  approximately  60%  of  children  achieve  complete
seizure  freedom  once  they  are  established  on  a  therapeu-
tic  dose  their  ﬁrst  AED.  It  is  not  currently  possible  to  predict
reliably  which  children  will  respond  well  to  AEDs,  although
certain  risk  factors,  such  as  age  of  onset  <1  year,  structural
or  metabolic  etiology,  developmental  impairment,  and  high
frequency  of  seizures  before  treatment  initiation  increase
the  likelihood  that  the  epilepsy  will  be  refractory.32,33
Evidence-based  AED  treatmentThere  are  26  AEDs  currently  licensed  for  treatment  of
epilepsy  in  childhood.  Among  these  medications,  the  older
ones  have  attained  their  license  through  longstanding  estab-
lished  use,  and  the  newer  ones  were  generally  licensed  after
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emonstrating  a >50%  reduction  in  seizure  frequency  when
sed  as  add-on  therapy  in  refractory  epilepsy.  Meanwhile,
he  evidence  base  for  which  AED  to  use  as  ﬁrst  line  treatment
emains  limited,  with  very  few  studies  measuring  long-term
utcomes.
The  choice  of  initial  treatment  should  take  into
ccount  the  seizure  type(s),  epilepsy  syndrome,  age,  eti-
logy,  comorbidities,  and  potential  interactions  with  other
edications.34
eneralized  or  focal  seizures
he  SANAD  trials  used  randomized  unblinded  methodol-
gy  to  compare  initial  treatment  options,  with  epilepsies
roadly  stratiﬁed  into  two  groups:  epilepsy  with  focal
eizures  (previously  termed  partial  epilepsy),  and  epilepsy
ith  generalized  seizures  (previously  termed  generalized
pilepsy).35,36 The  mean  age  of  subjects  was  38.3  years  in  the
ocal  group  and  22.5  years  in  the  generalized  group;  thus,
t  is  difﬁcult  to  say  whether  the  ﬁndings  are  fully  applica-
le  to  children.  Treatment  efﬁcacy  was  determined  by  the
roportion  of  patients  who  achieved  12-month  remission  2
ears  after  randomization.
In  the  focal  arm  of  SANAD,  1721  patients  were  ran-
omized  to  treatment  with  lamotrigine,  carbamazepine,
abapentin,  or  topiramate.  Both  lamotrigine  and  car-
amazepine  were  more  efﬁcacious  than  gabapentin  or
opiramate.  Lamotrigine  treatment  was  associated  with  sig-
iﬁcantly  fewer  side  effects  than  carbamazepine.
In  the  generalized  arm  of  SANAD,  716  patients  were
andomized  to  treatment  with  lamotrigine,  topiramate  or
odium  valproate.  Here  sodium  valproate  was  more  efﬁ-
acious  than  both  topiramate  and  lamotrigine.  Sodium
alproate  was  better  tolerated  than  topiramate,  with  no  sig-
iﬁcant  difference  in  tolerability  between  sodium  valproate
nd  lamotrigine.
yndrome-speciﬁc  AED  treatment
ery  few  trials  of  initial  AED  treatment  have  been  stratiﬁed
y  epilepsy  syndrome;  therefore,  treatment  decisions  are
enerally  guided  by  whether  focal  seizures  are  present  or
ot.  The  exception  here  is  CAE,  for  which  a  long-term  double
linded  trial  compared  ethosuximide,  sodium  valproate,  and
amotrigine  in  a  population  of  453  children.  Freedom  from
ailure  rates  at  12  months  were  as  follows:  ethosuximide
45%),  sodium  valproate  (44%),  and  lamotrigine  (21%).  There
as  statistically  signiﬁcant  superiority  of  ethosuximide  and
odium  valproate  over  lamotrigine.  The  sodium  valproate
roup  experienced  the  most  undesirable  side  effects,  most
otably  attention  dysfunction.
Another  syndrome  for  which  there  is  emerging  evidence
or  speciﬁc  AED  treatment  is  WS,  which  is  deﬁned  by
he  coexistence  of  infantile  spasms  and  hypsarrhythmia  on
EG.  The  syndrome  starts  in  infancy,  is  frequently  associ-
ted  with  developmental  regression,  and  may  evolve  into
ennox--Gastaut  syndrome.  Weak  evidence  from  retrospec-
ive  cohorts  has  traditionally  led  many  clinicians  to  use
ither  vigabatrin  or  corticosteroid  therapy.  In  a  head-to  head
nblinded  trial,  there  was  no  difference  in  seizure  control
t  12--24  months  of  age  between  both  treatment  options.37
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t  has  been  recently  demonstrated  that  combined  therapy
ith  both  vigabatrin  and  corticosteroids  results  in  improved
eizure  outcomes  at  12--24  months  of  age  when  compared
ith  corticosteroid  therapy  alone.38
There  are  no  other  syndrome-speciﬁc  AED  approaches
ased  on  grade  1  or  2  clinical  evidence.  There  are  sev-
ral  clinical  reports  of  patients  with  myoclonic  seizures
xperiencing  a  deterioration  in  myoclonus  when  sodium
hannel-blocking  medications  are  started.  Sodium  channel
lockers  include  carbamazepine,  lamotrigine,  and  pheny-
oin.  These  AEDs  are  therefore  often  avoided  in  syndromes
haracterized  by  myoclonic,  seizures  such  as  JME39 and
ravet  syndrome.40
tiology-speciﬁc  therapy
reating  epilepsy  by  etiology  is  an  attractive  concept,  since
argeting  the  underlying  disease  mechanism  would  appear
o  be  a  more  speciﬁc  approach.  Epilepsy  can  be  secondary
o  a  great  number  of  individually  rare  inherited  metabolic
iseases,  and  when  speciﬁc  treatment  for  these  is  initi-
ted  seizure  control  often  improves.  Pyridoxine  dependency
nd  GLUT1  deﬁciency  syndrome  may  present  with  severe
pilepsy  that  is  refractory  to  AED  therapy,  but  respond  very
ell  to  speciﬁc  treatment  with  pyridoxine  and  the  ketogenic
iet,  respectively.
Recent  advances  in  genetic  understanding  of  epilepsy
ay  in  future  lead  to  the  stratiﬁcation  of  patients  with
pilepsy  into  gene-speciﬁc  AED  therapy,  though  large
ohorts  will  be  required  to  build  a  strong  evidence  base.
romising  results  have  been  observed  with  everolimus
reatment  for  patients  with  tuberous  sclerosis,41 and
tiripentol  treatment  in  Dravet  syndrome,  a  severe  epileptic
ncephalopathy  whose  onset  is  in  infancy,  caused  by  muta-
ions  in  the  SCN1A  gene.42
onitoring  therapy
egular  monitoring  of  antiepileptic  drug  levels  is  rarely  indi-
ated.  The  best  way  to  monitor  for  toxicity  is  to  keep  the
atient  under  regular  follow-up  and  to  recommend  that  the
amily  seek  medical  attention  if  they  notice  any  potential
ide  effects.  AEDs  are  generally  much  better  tolerated  if
hey  are  introduced  at  a  low  dose,  which  is  incrementally
itrated  upwards.  Checking  AED  levels  may  be  useful  for  cer-
ain  medications  with  a  narrow  therapeutic  window,  such  as
henytoin,  phenobarbital,  and  triple  bromide,  and  in  situa-
ions  of  treatment  failure  and  where  it  is  suspected  that
ubtherapeutic  levels  may  be  being  achieved.
efractory  epilepsy
hen  the  ﬁrst  AED  does  not  work,  how  to  select  the
econd  one?
f  seizure  freedom  is  not  achieved  with  the  ﬁrst  AED,
he  chance  of  attaining  complete  remission  with  a  sec-
nd  AED  is  40%.43 For  every  AED  that  is  unsuccessful,
he  chances  of  achieving  remission  with  a  different  AED
iminish  proportionately.  Ultimately,  one-third  of  children
ith  epilepsy  will  continue  to  have  epileptic  seizures
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egardless  of  medication.44 The  ILAE  has  set  forth  a
ractical  deﬁnition  of  drug-resistant  epilepsy  as  epilepsy
n  which  two  appropriately  chosen  and  appropriately
osed  AEDs  have  been  administered  without  remission  of
eizures.45
Choice  of  second-line  AED  therapy  has  no  evidence  base.
here  is  also  no  evidence  that  polytherapy  is  more  efﬁca-
ious  than  alternative  monotherapy.  In  the  ﬁrst  instance,
ost  clinicians  will  try  alternative  monotherapy,  although
here  will  typically  be  a  period  of  overlap  whilst  one  AED
s  gradually  withdrawn  and  another  is  introduced.  Once
wo  or  more  monotherapy  approaches  have  been  unsuc-
essful,  a  polytherapy  approach  may  then  be  tried.  When
onsidering  polytherapy,  interactions  between  AEDs  must
e  considered,  as  this  may  affect  dosing.  For  example,
he  lamotrigine  dose  should  be  halved  when  adminis-
ered  concomitantly  with  sodium  valporate  due  to  the
nzyme-inhibiting  properties  of  the  latter.  It  is  generally
ecommended  that  the  AED  regimen  does  not  include  med-
cations  with  the  same  broad  mechanism  of  action.  For
xample,  both  carbamazpeine  and  lamotrigine  are  sodium
hannel-blockers,  so  one  should  be  cautious  about  using
hese  two  simultaneously.
hen  multiple  AEDs  fail  to  work
or  children  with  refractory  epilepsy  with  focal  seizures,
urgical  treatment  should  be  considered.  In  randomized  tri-
ls  of  surgery  versus  additional  AED  therapy  in  carefully
elected  surgical  candidates,  the  proportion  of  these  chil-
ren  who  become  seizure-free  after  surgery  is  signiﬁcantly
reater  than  those  randomized  to  receive  an  additional  AED.
omprehensive  preoperative  evaluation  involves  a  multidis-
iplinary  approach  to  pinpoint  the  epileptogenic  zone  of
he  brain  as  the  appropriate  surgical  target.  High-resolution
euroimaging,  ictal  EEG,  dynamic  ictal  radionucelotide
can  (such  as  single  photon-emission  computed  tomogra-
hy  [SPECT]),  and  detailed  neuropsychological  evaluation
re  all  useful  tools  in  this  regard.  Between  30%  and  80%  of
ediatric  patients  achieve  long-term  seizure-freedom  fol-
owing  epilepsy  surgery46; Non-resective  surgical  options
ay  be  used  in  highly  speciﬁc  situations.  For  example,
nterhemispheric  disconnection  may  be  used  in  cases  where
eizures  originating  from  one  hemisphere  are  frequently
eneralizing.
Another  alternative  to  further  AED  trials  in  refractory
pilepsy  is  the  ketogenic  diet,  which  uses  a  highly  special-
zed  diet  to  maintain  the  presence  of  ketone  bodies  in  the
ystemic  circulation.  Ketone  bodies  appear  to  have  an  anti-
pileptic  effect,  although  the  exact  mechanism  is  not  well
nderstood.  The  ketogenic  diet  appears  to  be  equally  as  efﬁ-
acious  as  add-on  AED  therapy.  In  one  study  16%  of  children
ith  refractory  epilepsy  became  seizure-free  on  the  diet.47
or  some  families,  administration  of  the  ketogenic  diet  may
e  challenging.
Vagus  nerve  stimulation  (VNS)  is  another  technique  that
s  often  used  in  refractory  epilepsies.  However,  it  should
nly  be  used  once  comprehensive  surgical  evaluation  has
xcluded  the  possibility  of  targeted  lesional  treatment.
eizure  freedom  is  rarely  observed  with  VNS,  and  it  has  not
een  established  whether  VNS  is  any  more  effective  than
dditional  AED  therapy.48
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Speciﬁc  situations
Clusters
Although  there  is  no  accepted  deﬁnition  of  cluster  seizures,
it  is  well  accepted  that  patients  with  refractory  epilepsy
can  go  through  self-limited  periods  of  signiﬁcantly  wors-
ened  seizure  control.  Such  periods  are  often  precipitated  by
stress,  intercurrent  illness,  or  sleep  deprivation.  There  have
been  no  clinical  trials  to  inform  clinicians  how  best  to  man-
age  these  situations,  but  many  have  experienced  that  a short
course  of  a  long-acting  benzodiazepine,  such  as  clobazam,
can  be  effective.
Status  epilepticus
Status  epilepticus  refers  to  any  seizure  lasting  longer  than
30  min,  or  multiple  seizures  without  restitution  of  nor-
mal  conscious  level  between  events.  It  may  classiﬁed
as  convulsive,  focal,  autonomic,  or  absence.  The  recom-
mended  ﬁrst  line  therapy  is  a  benzodiazepine,  which  may  be
administered  rectally  (diazepam),  orally  or  nasally  (midazo-
lam),  or  intravenously  (lorazepam  or  diazepam).  If  seizures
persist  despite  one  dose  of  benzodiazepine,  a  second  ben-
zodiazepine  dose  may  be  given.49 Treatment  for  status
epilepticus  following  two  ineffective  doses  of  benzodi-
azepine  has  no  evidence  base,  and  responses  to  therapy  may
be  highly  individual.  Options  include  rectal  paraldehyde,  IV
phenytoin,  IV  phenobarbital,  IV  sodium  valproate,  and  IV
levetiracetam.  It  is  recommended  that  children  prone  to
episodes  of  status  epilepticus  have  their  personalized  treat-
ment  plans  kept  both  by  the  family,  and  by  any  emergency
department  where  they  are  likely  to  be  received.  For  the
treatment  of  children  without  personalized  plans,  emer-
gency  departments  should  have  generic  protocols  in  place  to
ensure  prompt  management  and  appropriate  dosing.34 The
differential  diagnosis  of  status  epilepticus  is  easy  to  overlook
in  the  heat  of  the  emergency  situation,  but  consideration
should  be  given  to  the  possibility  of  non-epileptic  status,
and  to  increased  intracranial  pressure,  in  which  decorticate
posturing  may  mimic  convulsive  activity.  Administration  of  a
high  dose  blood  pressure-lowering  anticonvulsants  can  have
signiﬁcant  adverse  effects  in  cases  of  increased  intracranial
pressure.
Pregnancy
For  women  of  childbearing  age  with  epilepsy,  consideration
needs  to  be  given  to  the  potential  teratogenic  effects  of
medication.  The  risk  to  an  unborn  fetus  from  poorly  con-
trolled  epilepsy  outweighs  the  teratogenic  risk  conferred
from  any  AED,  but  there  is  now  clear  evidence  that  sodium
valproate  is  signiﬁcantly  more  teratogenic  than  the  other
AEDs,  with  5.7--16.8%  of  pregnancies  affected.  Therefore,
for  patients  with  newly  diagnosed  epilepsy,  if  they  may
become  pregnant  in  the  next  few  years,  it  is  advisable
to  commence  them  on  a  medication  other  than  sodium
valproate.50
Discontinuation  of  therapyFor  children  who  have  been  seizure-free  on  medication
for  over  2  years  on  monotherapy,  discontinuation  of  AED
treatment  should  be  considered,  particularly  if  there  is  no
C
TS75
tructural  or  metabolic  underlying  etiology.  In  children  in
hom  AED  therapy  is  withdrawn  after  2  years  of  seizure
reedom,  70%  will  remain  seizure-free  for  the  subsequent
 years.51
udden  unexpected  death  in  epilepsy  and  mortality
n  a  Finish  cohort  of  245  patients  with  childhood-onset
pilepsy  followed-up  over  40  years,  the  overall  standardized
ortality  rate  was  calculated  as  6.4/1000  patient-years,
hich  is  approximately  1.5  times  that  of  the  general  popula-
ion.  The  vast  majority  of  deaths  occurred  in  adulthood,  and
alf  were  not  related  to  epilepsy.  Sudden  unexpected  death
n  epilepsy  (SUDEP)  accounted  for  23/33  epilepsy-related
eaths  in  this  cohort.  The  major  risk  factors  for  increased
ortality  are  structural  or  metabolic  etiology,  frequency  of
eizures,  and  the  presence  of  nocturnal  seizures.52 Children
ith  uncomplicated  epilepsy  do  not  appear  to  be  at  risk  of
UDEP.
uture directions
espite  major  recent  advances  in  the  understanding  of
pilepsy  etiology,  and  the  emergence  of  a number  of  new
EDs,  the  proportion  of  childhood-onset  epilepsies  that  are
efractory  to  treatment  has  largely  remained  unchanged.  To
ddress  this  issue,  there  is  a clear  need  for  a  more  strati-
ed  approach  to  treatment.  Traditionally,  stratiﬁcation  has
een  by  broad  seizure  type  (focal  or  generalized),  and  only
ccasionally  by  epilepsy  syndrome.  With  the  emergence  of
enetic  technology  it  is  possible  that  in  the  future,  stratiﬁ-
ation  will  be  done  by  genotype.  In  order  to  build  a  useful
vidence  base,  large  multicenter  trails  are  needed.
onclusion
hildhood-onset  epilepsies  are  a  heterogeneous  group  of  dis-
rders  with  a  wide  variety  of  causes  and  an  equally  wide
ariety  of  presentations.  The  majority  of  patients  achieve
eizure  freedom  with  treatment  on  a single  AED,  which  must
e  chosen  appropriately.  Successful  management  needs  to
e  underscored  by  a  structured  approach  to  diagnosis,  which
hould  take  a  multi-axial  approach.  Recent  advances  in  the
nderstanding  of  epilepsy  etiology  and  pathophysiology  have
esulted  in  a reconceptualization  of  the  classiﬁcation  of
pilepsies.  Despite  the  scientiﬁc  advances,  and  despite  the
evelopment  of  a  number  of  new  AEDs,  a  signiﬁcant  treat-
ent  gap  still  exists,  with  a  proportion  of  patients  having
efractory  disease.  For  some  carefully  selected  patients,
pilepsy  surgery  can  lead  to  remission,  but  successful
urgery  must  be  underpinned  by  comprehensive  pre-surgical
valuation.  A  personalized  medical  approach  using  stratiﬁed
reatment  schemes  may  help  to  deliver  better  outcomes  in
uture.  In  order  to  achieve  this,  global  efforts  must  be  made
o  establish  a  robust  evidence  base.onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
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